Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma

被引：0
|
作者：
Astrid Lièvre
Bérèngere Ouine
Jim Canet
Aurélie Cartier
Yael Amar
Wulfran Cacheux
Odette Mariani
Rosine Guimbaud
Janick Selves
Thierry Lecomte
Serge Guyetant
Ivan Bieche
Frédérique Berger
Leanne de Koning
机构：
[1] CHU Pontchaillou,Service des maladies de l’appareil digestif
[2] Université Rennes 1,Faculté de médecine
[3] Rue Bataille Flandres-Dunkerque,Inserm ER440
[4] Institut Curie,Oncogenesis, Stress and Signaling
[5] PSL Research University,Department of Translational Research
[6] PSL Research University,Institut Curie
[7] Unit of Biostatistics,Department of Medical Oncology, Institut Curie
[8] René Huguenin Hospital,Department of Genetics, Institut Curie
[9] Unit of Pharmacogenomics,Biological Resource Center, Institut Curie
[10] PSL Research University,Centre de Recherche en Cancérologie de Toulouse, Unité Mixte de Recherche
[11] 26 rue d’Ulm,Service d’oncologie médicale
[12] 1037 INSERM—Université Toulouse III,Department of Pathology
[13] Centre Hospitalier Universitaire de Toulouse,Hôpital Trousseau—CHRU de TOURS
[14] Centre Hospitalier Universitaire de Toulouse,UMR CNRS 7292 (GICC)
[15] Service d’Hépato-Gastro-Entérologie,Hôpital Trousseau—CHRU de TOURS
[16] Université François Rabelais,Institut Curie
[17] Service d’Anatomie et Cytologie Pathologiques—Tumorothèque,undefined
[18] PSL Research University,undefined
[19] INSERM U900,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Supplementary Table 1 and the Supplementary Figure legends were not included when this manuscript was first published. The files are now available here.
引用
收藏
页码：387 / 387
相关论文
共 50 条
  • [21] EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer
    Carpen, Olli
    Algars, Annika
    Sundstrom, Jari
    Kytola, Soili
    Osterlund, Pia
    Lintunen, Minnamaija
    Jokilehto, Terhi
    Kaare, Milja
    Orpana, Arto
    Vainionpaa, Reetta
    Ristimaki, Ari
    Ristamaki, Raija
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
    Cristiana Lo Nigro
    Vincenzo Ricci
    Daniela Vivenza
    Cristina Granetto
    Teresa Fabozzi
    Emanuela Miraglio
    Marco C Merlano
    World Journal of Gastroenterology, 2016, (30) : 6944 - 6954
  • [23] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
    Lo Nigro, Cristiana
    Ricci, Vincenzo
    Vivenza, Daniela
    Granetto, Cristina
    Fabozzi, Teresa
    Miraglio, Emanuela
    Merlano, Marco C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (30) : 6944 - 6954
  • [24] First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
    Ottaiano, Alessandro
    De Stefano, Alfonso
    Capozzi, Monica
    Nappi, Anna
    De Divitiis, Chiara
    Romano, Carmela
    Silvestro, Lucrezia
    Cassata, Antonino
    Casaretti, Rossana
    Tafuto, Salvatore
    Caraglia, Michele
    Berretta, Massimiliano
    Nasti, Guglielmo
    Avallone, Antonio
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [25] The efficacy of anti-EGFR therapy across different lines of treatment in RAS wild-type left-sided metastatic colorectal cancer.
    Akewanlop, Charuwan
    Korphaisarn, Krittiya
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 86 - 86
  • [26] Treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC): Continuation of anti-EGFR therapy while switching chemotherapy regimen.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    Kit, Oleg Ivanovich
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [27] Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study
    Palmieri, L-J.
    Mineur, L.
    Tougeron, D.
    Rousseau, B. J-C.
    Granger, V.
    Gornet, J-M.
    Smith, D.
    Lievre, A.
    Galais, M. P.
    Doat, S. Racine
    Pernot, S.
    Bretagne, A. L. Bignon
    Metges, J-P.
    Baba-Hamed, N.
    Hassine, M.
    Obled, S.
    Vitellius, C.
    Bouche, O.
    Vernerey, D.
    Coriat, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials
    Kagawa, Y.
    Kotani, D.
    Bando, H.
    Takahashi, N.
    Horita, Y.
    Kanazawa, A.
    Kato, T.
    Ando, K.
    Satake, H.
    Shinozaki, E.
    Sunakawa, Y.
    Takashima, A.
    Yamazaki, K.
    Yuki, S.
    Nakajima, H.
    Nakamura, Y.
    Wakabayashi, M.
    Taniguchi, H.
    Ohta, T.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S244 - S244
  • [29] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    Rowland, A.
    Dias, M. M.
    Wiese, M. D.
    Kichenadasse, G.
    McKinnon, R. A.
    Karapetis, C. S.
    Sorich, M. J.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1888 - 1894
  • [30] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    A Rowland
    M M Dias
    M D Wiese
    G Kichenadasse
    R A McKinnon
    C S Karapetis
    M J Sorich
    British Journal of Cancer, 2015, 112 : 1888 - 1894
12345